Fed. Circ. Asks Whether Endo's Opioid Patent Was Obvious
Actavis LLC and Endo Pharmaceuticals Inc. faced questions from a Federal Circuit panel on Thursday regarding whether someone of ordinary skill could successfully develop Endo's opioid painkiller Opana ER, amid Actavis'...To view the full article, register now.
Already a subscriber? Click here to view full article